StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE:BTX opened at $6.54 on Friday. The company has a market cap of $384.72 million, a P/E ratio of -2.88 and a beta of 4.61. The stock’s fifty day moving average price is $3.25 and its two-hundred day moving average price is $1.69. Brooklyn ImmunoTherapeutics has a 1 year low of $6.35 and a 1 year high of $8.31.

Brooklyn ImmunoTherapeutics Announces Dividend

The business also recently announced a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be given a dividend of $0.0862 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.03 annualized dividend and a dividend yield of 15.81%. Brooklyn ImmunoTherapeutics’s dividend payout ratio is currently -38.33%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.